mission & values to serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. we value partnership and integrity, we are ethical and responsible and show respect and compassion for our patients. r&d strategy the successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. r&d is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. the advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. our innovative r&d is centered on patients’ needs and delivering affordable, safe and effective solutions. not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & developm
Company profile
Ticker
NLSP, NLSPW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NLSP stock data
Latest filings (excl ownership)
6-K
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
19 Apr 24
6-K
Report of Foreign Private Issuer
15 Apr 24
6-K
Report of Foreign Private Issuer
8 Apr 24
D
$1.75 mm in equity / options / securities to be acquired, sold $1.75 mm, 2 investors
3 Apr 24
424B5
Prospectus supplement for primary offering
22 Mar 24
6-K
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
21 Mar 24
6-K
Report of Foreign Private Issuer
20 Mar 24
6-K
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation
20 Mar 24
6-K
Report of Foreign Private Issuer
19 Mar 24
6-K
Report of Foreign Private Issuer
14 Mar 24
Latest ownership filings
SC 13G
Lind Global Fund II LP
27 Mar 24
SC 13G/A
YA II PN, Ltd.
12 Feb 24
SC 13G
Grisard Felix
24 Feb 23
SC 13G/A
Magnetic Rock Investment AG
14 Feb 23
SC 13G/A
Konofal Eric
14 Feb 23
SC 13G/A
Zwyer Alexander
13 Feb 23
SC 13G/A
YA II PN, Ltd.
3 Jan 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
16 Dec 22
SC 13G
Konofal Eric
24 Feb 22
SC 13G
Magnetic Rock Investment AG
18 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
64.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 7.16 bn |
Total shares | 20.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 6.86 mm | $5.94 mm |
BVF | 5.75 mm | $6.32 bn |
YA II PN | 3.05 mm | $0.00 |
Magnetic Rock Investment | 2.85 mm | $0.00 |
Hirschman Orin | 577.19 k | $3.38 mm |
Armistice Capital | 500.00 k | $53.50 mm |
Affinity Asset Advisors | 400.00 k | $440.00 mm |
J. Goldman & Co | 204.33 k | $224.76 mm |
Altium Capital Management | 200.00 k | $21.40 mm |
Ayrton Capital | 170.10 k | $18.20 mm |
Press releases
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
19 Apr 24
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
22 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
20 Mar 24
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
20 Mar 24
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
14 Mar 24